Blue Jet Healthcare Ltd
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
- Market Cap ₹ 6,671 Cr.
- Current Price ₹ 385
- High / Low ₹ 433 / 319
- Stock P/E 41.8
- Book Value ₹ 44.6
- Dividend Yield 0.00 %
- ROCE 35.4 %
- ROE 26.5 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 36.7%
Cons
- Stock is trading at 8.62 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| 538 | 499 | 683 | 721 | |
| 325 | 292 | 434 | 502 | |
| Operating Profit | 214 | 207 | 249 | 219 |
| OPM % | 40% | 41% | 36% | 30% |
| 6 | 9 | 19 | 24 | |
| Interest | 7 | 5 | 3 | 1 |
| Depreciation | 18 | 20 | 22 | 25 |
| Profit before tax | 194 | 190 | 243 | 217 |
| Tax % | 25% | 26% | 25% | 26% |
| 145 | 142 | 182 | 160 | |
| EPS in Rs | 24,118.33 | 1,428.57 | 10.47 | 9.23 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 10% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 3% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 37% |
| Last Year: | 27% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 10 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 739 |
| Preference Capital | 0 | 2 | 0 | 0 | |
| 74 | 52 | 19 | 5 | 2 | |
| 92 | 145 | 173 | 176 | 188 | |
| Total Liabilities | 364 | 536 | 713 | 862 | 964 |
| 107 | 0 | 156 | 151 | 185 | |
| CWIP | 2 | 3 | 3 | 30 | 64 |
| Investments | 26 | 37 | 94 | 189 | 211 |
| 229 | 497 | 460 | 491 | 504 | |
| Total Assets | 364 | 536 | 713 | 862 | 964 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| 122 | 137 | 146 | 142 | |
| -45 | -61 | -76 | -147 | |
| -72 | -21 | -56 | -4 | |
| Net Cash Flow | 5 | 55 | 14 | -10 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 |
| Inventory Days | 120 | 201 | 133 | 137 |
| Days Payable | 90 | 101 | 72 | 58 |
| Cash Conversion Cycle | 110 | 204 | 183 | 199 |
| Working Capital Days | 64 | 105 | 105 | 121 |
| ROCE % | 58% | 52% | 35% |
Documents
Announcements
- Reg 40(10) For The Year Ended March 31, 2024 17 Apr
- Compliance Certificate For The Year Ended March 31, 2024. 11 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr
- Closure of Trading Window 27 Mar
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
14 Feb - Of Transcript of the Earnings Call with Analyst/Investors on Financial Results for the third quarter and nine months ended December, 2023
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
Product Portfolio
A) Contrast media intermediates (70.5% of FY23 revenue)[1]
Contrast media are agents used in medical imaging to enhance visibility of body tissues under X-rays, computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound.